KAM
IRLA

Knightsbridge Asset Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Knightsbridge Asset Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,143
Closed -$344K – 113
2023
Q2 		$344K Buy
+1,143
New +$356K 0.11% 85

Other funds holding IRLA

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Knightsbridge Asset Management's IRLA Position: Q3 2023 in Review

Knightsbridge Asset Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2023, closing a stake of 1,143 shares — an estimated $344K sold.

Knightsbridge Asset Management first reported a position in IRLA in Q2 2023 and held it in 1 quarter. The position peaked at $344K in Q2 2023. 40 funds tracked by Wall St. Rank hold IRLA as of Q3 2023.

  • Knightsbridge Asset Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Knightsbridge Asset Management sold 1,143 IRulya Therapeutics Inc. Common Stock shares in Q3 2023, an estimated $344K.
  • Knightsbridge Asset Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Knightsbridge Asset Management's IRulya Therapeutics Inc. Common Stock position peaked at $344K in Q2 2023.
  • 40 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2023.

Based on Knightsbridge Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.